Revolution Medicines, Inc. (RVMDW) stock
RVMDWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMD
$9.81+0.18 (+1.82%)
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
Revolution Medicines ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Revolution Medicines's ebitda for the twelve months ending Jun 30, 2026 was -$1.62B. For fiscal 2025 it was -$1.17B. The highest annual figure on record is -$38.76M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.17B | – |
| FY2024 | Dec 31, 2024 | -$682.97M | – |
| FY2023 | Dec 31, 2023 | -$482.14M | – |
| FY2022 | Dec 31, 2022 | -$254.31M | – |
| FY2021 | Dec 31, 2021 | -$184.91M | – |
| FY2020 | Dec 31, 2020 | -$108.09M | – |
| FY2019 | Dec 31, 2019 | -$51.85M | – |
| FY2018 | Dec 31, 2018 | -$38.76M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$502.68M | – |
| Q1 FY2026 | Mar 31, 2026 | -$442.88M | – |
| Q4 FY2025 | Dec 31, 2025 | -$359.36M | – |
| Q3 FY2025 | Sep 30, 2025 | -$313.74M | – |
| Q2 FY2025 | Jun 30, 2025 | -$262.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$239.07M | – |
| Q4 FY2024 | Dec 31, 2024 | -$214.58M | – |
| Q3 FY2024 | Sep 30, 2024 | -$174.07M | – |
| Q2 FY2024 | Jun 30, 2024 | -$155.00M | – |
| Q1 FY2024 | Mar 31, 2024 | -$139.32M | – |
| Q2 FY2023 | Jun 30, 2023 | -$107.57M | – |
| Q1 FY2023 | Mar 31, 2023 | -$73.95M | – |
| Q4 FY2022 | Dec 31, 2022 | -$60.56M | – |
| Q3 FY2022 | Sep 30, 2022 | -$75.53M | – |
| Q2 FY2022 | Jun 30, 2022 | -$61.19M | – |
| Q1 FY2022 | Mar 31, 2022 | -$57.05M | – |
| Q4 FY2021 | Dec 31, 2021 | -$52.08M | – |
| Q3 FY2021 | Sep 30, 2021 | -$52.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$43.74M | – |
| Q1 FY2021 | Mar 31, 2021 | -$36.73M | – |
| Q4 FY2020 | Dec 31, 2020 | -$33.41M | – |
| Q3 FY2020 | Sep 30, 2020 | -$26.85M | – |
| Q2 FY2020 | Jun 30, 2020 | -$27.38M | – |
| Q1 FY2020 | Mar 31, 2020 | -$20.45M | – |
| Q4 FY2019 | Dec 31, 2019 | -$18.97M | – |
| Q3 FY2019 | Sep 30, 2019 | -$12.96M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.06M | – |
| Q1 FY2019 | Mar 31, 2019 | -$9.91M | – |